Associate Professor Michael Hill
Laboratory Scientific Director
- MRC PHRU Director of Laboratories
Associate Professor Mike Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Mike works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2005; No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.
Allen RJ. et al, (2019), Am J Respir Crit Care Med
Shared immunogenetic associations across common pathogens discovered through Multiplex Serology screening in UK Biobank
Chong AY. et al, (2019), EUROPEAN JOURNAL OF HUMAN GENETICS, 27, 1359 - 1360
General and Abdominal Adiposity and Mortality in Mexico City: Prospective Study of 150 000 Adults.
Gnatiuc L. et al, (2019), Ann Intern Med
Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults.
Sun L. et al, (2019), Nat Med, 25, 569 - 574
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int